YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstandi…
TransMedics Group has seen its share price slide in recent months after a strong multi‑year run, which raises an obvious question for you as an investor. Is the current US$78.64 price still aligned with what the company is earning today, o…
TransMedics Group (TMDX) has drawn investor attention after recent trading left the stock around $78.64, with returns down over the past month but higher over the past three months and three years. Short term momentum for TransMedics Group…
Major U.S. market indexes have performed well this year and are near all-time highs, but that's largely driven by large technology and artificial intelligence-focused companies. It's not that hard to find beaten-down stocks once we step ou…
ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as…
TransMedics Group, Inc. TMDX is still expanding at a rapid pace, with Organ Care System adoption and transplant logistics supporting higher revenues. Management also raised the low end of its 2026 revenue outlook. The trade-off is profitab…
A month has gone by since the last earnings report for TransMedics (TMDX). Shares have added about 10.2% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up…
[short sale] abluecup As September begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 44 stocks with short interest above 20% of shares outstan…
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, to…
NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If…
TransMedics Group TMDX delivered earnings per share (EPS) of 44 cents in the second quarter of 2026, down 52.2% year over year. The figure missed the Zacks Consensus Estimate by 12%. TMDX Revenue Mix Shows Service Strength Revenues rose 20…
Shares of leading, next-gen organ transplant systems specialist TransMedics (NASDAQ: TMDX) are down 8% as of 1 p.m. ET Wednesday after the company reported underwhelming second-quarter earnings. Sales growth of 21% beat analysts' hopes, bu…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Wednesday. U.S. stock index futures rose on Wednesday as Wall Street looked to continue…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. TransMedics Group stock has delivered a 170.9% gain over the past f…
This article first appeared on GuruFocus. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Record Q2 2026 revenue of ~$190 million, up 21% ye…
For the quarter ended June 2026, TransMedics (TMDX) reported revenue of $189.95 million, up 20.7% over the same period last year. EPS came in at $0.44, compared to $0.92 in the year-ago quarter. The reported revenue compares to the Zacks C…
TransMedics (TMDX) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items. Th…
ANDOVER, Mass., Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, tod…
TransMedics Group, Inc. previously announced it would report its Q2 2026 results after the market close on August 4, 2026, alongside an earnings call, while also granting stock options and restricted stock units to new employees under Nasd…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. TransMedics Group (TMDX) heads into a busy early August, with Q2 2026 results and an earnings call…
ANDOVER, Mass., Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, tod…
The market expects RxSight, Inc. (RXST) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's…
ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, to…
TransMedics (TMDX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings pic…
[Annual report under review] Willie B. Thomas In its Q2 portfolio update, Next Century Growth Investors disclosed nine new positions across three sectors. The industrial additions were Park Aerospace Corp. (PKE [https://seekingalpha.com/sy…
ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, tod…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The Health Care Select Sector SPDR® Fund ETF (XLV [https://seekingalpha.com/symbol/XLV]), which tracks the health car…
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Atlas Healthcare Fund managed by VST Capital, today highlighted a series of early conviction investment decisions that have defined its track record since launch — none more striking than its pos…
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. TransMedics Group, Inc. (NASDAQ:TMDX) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI analyst Daniel Markowit…
TransMedics Group TMDX recently completed its strategic investment in Germany-based PAD Aviation service GmbH, marking a key step in expanding its Organ Care System ("OCS") National OCS Program ("NOP") model into Europe. The investment is…
StrategicinvestmentinGermany-basedPADAviation,apremierEuropeanprivateaviationoperator,laysthefoundationfor TransMedics to establish a dedicated organ transplantation air logistics network acrossEurope ANDOVER, Mass., July 6, 2026 /PRNewswi…
Every year in the United States, roughly 100,000 people sit on transplant waiting lists. Some will wait years. Others won't make it. The problem isn't only a shortage of willing donors; it's that the organs that do become available often d…
Key Points TransMedics is building more than a medical device business. Its Organ Care System and nationwide transplant logistics network create a difficult-to-replicate competitive advantage. With more than 90,000 Americans waiting for ki…
Key Points Investing in attractive stocks on the dip is a great way to earn above-average returns over the long run. The three stocks below have faced some challenges, but their prospects look fairly strong. 10 stocks we like better than S…
The best time to buy a stock may be when it is experiencing a temporary pullback from which it will likely bounce back, rather than during a strong bull run with little -- if any -- additional upside. Thankfully, even as broader equities c…
TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System (OCS) technology. The optimism, led by decent first-quarter 2026 results, is expected to contribute further. Howev…